VIVA Biotech (01873) surged more than 20% in afternoon trading. As of press time, the stock was up 19.59% at HK$1.77, with a turnover of HK$32.0124 million.

On the news front, VIVA Biotech recently entered into an AI-driven reverse target discovery research and development collaboration with Xidian Pharmaceutical. Leveraging VIVA Biotech's Mol2MARS platform, the two parties conducted systematic research on the potential mechanisms of action and targets of drug molecules, establishing an innovative target discovery R&D closed loop of "AI computing plus experimental validation," providing new scientific evidence for the analysis of drug mechanisms of action and the expansion of indications.

According to China Merchants Securities, as of the first half of 2026, CADD/AIDD had cumulatively participated in 228 projects with 92 procurement clients; revenue from AI-empowered projects accounted for approximately 14.0% of CRO revenue, and revenue from wet lab experiments related to AI clients accounted for approximately 15.0%. The company upgraded and launched the MARS multimodal comprehensive algorithm platform, building significant technical barriers in the fields of peptides, cyclic peptides, and complex macrocyclic compounds, and comprehensively upgraded its three underlying modules.